Avrobio Inc (NASDAQ:AVRO) has been given an average broker rating score of 1.13 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and three have given a strong buy rating to the company.

Analysts have set a 1 year consensus price objective of $41.00 for the company and are predicting that the company will post ($0.54) EPS for the current quarter, according to Zacks. Zacks has also assigned Avrobio an industry rank of 103 out of 255 based on the ratings given to its competitors.

A number of analysts have recently weighed in on AVRO shares. Wedbush started coverage on shares of Avrobio in a research report on Monday, July 16th. They issued an “outperform” rating and a $38.00 target price on the stock. Morgan Stanley started coverage on shares of Avrobio in a research report on Monday, July 16th. They issued an “overweight” rating and a $37.00 target price on the stock. Cowen started coverage on shares of Avrobio in a research report on Monday, July 16th. They issued an “outperform” rating on the stock. Finally, Wells Fargo & Co started coverage on shares of Avrobio in a research report on Monday, July 16th. They issued an “outperform” rating and a $40.00 target price on the stock.

Shares of Avrobio stock opened at $40.00 on Friday. Avrobio has a 12-month low of $26.51 and a 12-month high of $44.01.

Avrobio (NASDAQ:AVRO) last released its earnings results on Thursday, August 9th. The company reported ($2.98) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($2.51). sell-side analysts expect that Avrobio will post -1.86 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in AVRO. TD Asset Management Inc. purchased a new stake in shares of Avrobio in the 2nd quarter worth about $217,000. Emerald Advisers Inc. PA bought a new position in Avrobio in the 2nd quarter worth about $6,845,000. Emerald Mutual Fund Advisers Trust bought a new position in Avrobio in the 2nd quarter worth about $6,026,000. Dean Capital Investments Management LLC bought a new position in Avrobio in the 2nd quarter worth about $549,000. Finally, SV Health Investors LLC bought a new position in Avrobio in the 2nd quarter worth about $78,141,000. 13.91% of the stock is currently owned by hedge funds and other institutional investors.

Avrobio Company Profile

AVROBIO, Inc, a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease.

Read More: Average Daily Trade Volume Explained

Get a free copy of the Zacks research report on Avrobio (AVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.